+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Meta-analysis on the comparison between two topical calcineurin inhibitors in atopic dermatitis



Meta-analysis on the comparison between two topical calcineurin inhibitors in atopic dermatitis



Journal of Dermatology 39(6): 520-526



Topical calcineurin inhibitors have proved to be suitable for the treatment of AD. We conducted a meta-analysis comparing efficacy and tolerance of tacrolimus with pimecrolimus in treatment of AD. According to our meta-analysis, tacrolimus 0.1% was more effective than pimecrolimus 1% in adult patients (week 3: risk ratio [RR] 0.55, 95% confidence interval [CI] 0.42-0.73), and tacrolimus (a combination of 0.03% and 0.1%) was also more effective than pimecrolimus 1% in pediatric patients (week 6/end of study: RR 0.76, 95% CI 0.63-0.92). Regardless of age or illness severity, tacrolimus 0.1% had higher efficacy than pimecrolimus 1% in the treatment of AD (week 3: RR 0.55, 95% CI 0.42-0.72). In adult patients, tacrolimus 0.1% had more adverse events than pimecrolimus 1% (RR 1.30, 95% CI 1.02-1.66), but the incidence of adverse events between tacrolimus 0.1% (or 0.03%) and pimecrolimus 1% was not significantly different in pediatric patients. No matter whether the patients were adult or pediatric, more pimecrolimus-treated patients withdrew from the trials because of a lack of efficacy. Regardless of age and illness severity, more pimecrolimus 1%-treated patients withdrew from the trials because of a lack of efficacy, compared with tacrolimus 0.1% (or 0.03%)-treated patients. More pimecrolimus-treated pediatric patients withdrew from the trials because of adverse events (RR 0.26, 95% CI 0.1-0.68). More pimecrolimus 1%-treated patients withdrew from the trials because of adverse events, compared with tacrolimus 0.03%-treated patients, regardless of age (RR 0.1, 95% CI 0.02-0.53). In conclusion, tacrolimus ointment has higher efficacy and better tolerance than pimecrolimus cream in treatment of AD.

(PDF emailed within 0-6 h: $19.90)

Accession: 036363567

Download citation: RISBibTeXText

PMID: 22409418

DOI: 10.1111/j.1346-8138.2012.01529.x


Related references

Retraction. “Meta-analysis on the comparison between two topical calcineurin inhibitors in atopic dermatitis” by Zhi Qiang Y, Wei Ming Z, Guo Xin S, and Dan L. Journal of Dermatology 40(5): 418-418, 2014

Topical calcineurin inhibitors in atopic dermatitis: a systematic review and meta-analysis. Journal of Dermatological Science 54(2): 76-87, 2009

Topical calcineurin inhibitors in the treatment of atopic dermatitis: a meta-analysis of current evidence. American Journal of Clinical Dermatology 5(4): 267-279, 2004

Systematic review and meta-analysis of randomized clinical trials (RCTs) comparing topical calcineurin inhibitors with topical corticosteroids for atopic dermatitis: A 15-year experience. Journal of the American Academy of Dermatology 75(2): 410-419.E3, 2017

Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials. Journal of Dermatological Treatment 21(3): 144-156, 2010

Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator-blind comparison. Journal of the American Academy of Dermatology 53(4): 602-609, 2005

Topical calcineurin inhibitors in pediatric atopic dermatitis: a critical analysis of current issues. Paediatric Drugs 9(5): 289-299, 2007

Topical corticosteroids and topical calcineurin inhibitors in the treatment of atopic dermatitis: focus on percutaneous absorption. American Journal of Therapeutics 16(3): 264-273, 2009

Use of topical corticosteroids and topical calcineurin inhibitors for the treatment of atopic dermatitis in thin and sensitive skin areas. Current Medical Research and Opinion 24(4): 985-994, 2008

Topical Calcineurin Inhibitors in Pediatric Atopic Dermatitis. Pediatric Drugs 9(5): 289-299, 2007

Topical Calcineurin Inhibitors in the Treatment of Atopic Dermatitis. American Journal of Clinical Dermatology 5(4): 267-279, 2004

The role of topical calcineurin inhibitors in atopic dermatitis. British Journal of Dermatology 151 Suppl 70 Dec 2004: 3-27, 2004

Role of topical calcineurin inhibitors on atopic dermatitis of children. Current Medicinal Chemistry 14(14): 1579-1591, 2007

The treatment of atopic dermatitis in adults with topical calcineurin inhibitors. Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete 54(5): 424-431, 2003

Safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. PharmacoTherapy 27(7): 1020-1028, 2007